...
首页> 外文期刊>Journal of Analytical Toxicology >Fatal intoxications associated with the designer opioid AH-7921.
【24h】

Fatal intoxications associated with the designer opioid AH-7921.

机译:与设计师阿片类药物AH-7921相关的致命性中毒。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide) is a designer opioid with ~80% of morphine's μ-agonist activity. Over a 6-month period, we encountered nine deaths where AH-7921 was involved and detected in blood from the deceased. Shortly after the last death, on August 1 2013, AH-7921 was scheduled as a narcotic and largely disappeared from the illicit market in Sweden. AH-7921 was measured by a selective liquid chromatography-MS-MS method and the concentrations of AH-7921 ranged from 0.03 to 0.99 μg/g blood. Six of our cases had other drugs of abuse on board and most had other medications such as benzodiazepines, antidepressants and analgesics. However, the other medicinal drugs encountered were present in postmortem therapeutic concentrations and unlikely to have contributed to death. In addition to the parent compound, we identified six possible metabolites where two N-demethylated dominated and four mono-hydroxylated were found in trace amounts in the blood. In conclusion, deaths with AH-7921 seem to occur both at low and high concentrations, probably a result of different tolerance to the drug. Hence, it is reasonable to assume that no sharp dividing line exists between lethal and non-lethal concentrations. Further, poly-drug use did not seem to be a major contributing factor for the fatal outcome.
机译:AH-7921(3,4-二氯-N-[(1-二甲基氨基)环己基甲基]苯甲酰胺)是一种阿片类药物,具有约80%的吗啡μ激动剂活性。在六个月的时间里,我们遇到了9例AH-7921死亡,并从死者的血液中发现了该死。上次死亡后不久,2013年8月1日,AH-7921被定为麻醉品,并在瑞典的非法市场上基本消失。 AH-7921通过选择性液相色谱-MS-MS方法进行测定,AH-7921的浓度范围为0.03至0.99μg/ g血液。我们的案件中有6个船上有其他滥用药物,而大多数有其他药物,例如苯二氮卓类,抗抑郁药和镇痛药。但是,所遇到的其他药物以死后治疗浓度存在,不太可能导致死亡。除母体化合物外,我们还鉴定了六个可能的代谢物,其中在血液中发现了痕量的两个N-去甲基化为主和四个单羟基化。总之,AH-7921的死亡似乎在低浓度和高浓度下都可能发生,这可能是由于对该药物的耐受性不同所致。因此,有理由假设在致死浓度和非致死浓度之间不存在明显的分界线。此外,使用多种药物似乎并不是致命后果的主要因素。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号